Ownership
Ownership in One Page
Senores Pharmaceuticals has a healthy ownership structure with stable promoter commitment and modest institutional participation. Promoters hold 45.8% with zero pledge as of March 2026—after a temporary pledge-and-release cycle (4L shares to Bajaj Finance in Feb 2026) that signalled short-term liquidity events but no structural stress. Institutional ownership (FII+DII) accounts for 13.3% of shares, with institutional investors adding 0.59% in the latest quarter, suggesting confidence from sophisticated capital. The free float of 54.2% is adequate for institutional positioning and daily liquidity. The stock has appreciated ~70% from its listing day close (Dec 2024 ₹559 listing close to current ₹948), with no index inclusion catalysts identified to date—this removes a near-term supply event but also limits passive demand drivers. Watch signal: Trading window reopens post-Q4 FY26 board approval (May 14 expected)—insider buying/selling activity will reveal confidence/concerns at current valuations.
Ownership at a Glance — March 2026
Ownership Structure (Latest Quarter)
Current shareholding breakdown as of March 2026 reflects a stable register with adequate public participation:
Shareholding Pattern — March 2026
Interpretation: The ownership structure is well-diversified with healthy free float. Promoters at 45.8% demonstrate continued commitment (no major planned dilutions). Institutional ownership at 13.3% (FII 3.64% + DII 9.62%) is modest but growing—the +0.59% addition in the latest quarter suggests institutional investors are building positions rather than exiting. Mutual funds at 4.88% represent the largest DII segment, with ICICI Prudential, Aditya Birla Sun Life, and SBI General Insurance as disclosed anchor investors from the December 2024 IPO. The 41% public holding provides sufficient liquidity and shields the stock from concentrated voting. No major institutional forced liquidations are evident.
Ownership Trend (IPO to Present)
Limited trend data available (company listed Dec 2024). Quarterly progression from IPO through March 2026:
Shareholding Pattern Trend (Dec 2024–Mar 2026)
Trend Analysis:
- Promoter: Stable at 45.8% throughout—zero selling, reaffirming long-term belief in the business.
- FII: Modest 3.4–4.5% range, with recent +0.24pp recovery in Q4. No crowding or panic; foreign institutional participation remains selective.
- DII: Reduced from 10.0% (IPO) to 9.3% (Dec 2025) then recovered to 9.62% (Mar 2026)—suggests DII portfolio rebalancing, not sector rotation or company-specific concerns.
- Public: Stable at 39–41%—retail participation is sticky and liquid.
Conclusion: Ownership is stable, not accumulating or distributing aggressively. This is a post-IPO normalized phase with no dramatic institutional flows. The slight Q4 institutional uptick (+0.59%) is positive but modest.
Promoter Health
Pledging Status:
Promoter Pledge History
Promoter Pledge Analysis:
The promoter register shows a clean pledge picture as of March 2026—a material positive signal. Timeline:
- Dec 2025: Espee Therapeutics LLP (promoter group entity) pledged 7,00,000 shares (~1.90% of promoter holding), likely to Bajaj Finance for short-term working capital.
- Feb 13, 2026: Espee pledged 4,00,000 shares to Bajaj Finance.
- Feb 13, 2026: All pledges released; promotional holding returned to pledge-free status by end of Q4 FY26.
Assessment: The February pledge-and-release cycle is a mild yellow flag—it indicates the promoter required short-term liquidity, possibly to fund capex or subsidiary investment. However, the rapid release within days suggests the liquidity event was tactical, not structural stress. The December 2025 pledge at ~2% of holdings is manageable and well below the 20% "watch" threshold. Current pledge = 0%; promoter has not re-pledged in April–May 2026 window, reaffirming confidence at current valuations.
Insider Trading: No material insider buying or selling disclosed in the available records (Q4 FY25–Q4 FY26). One minor transaction: Viraj Ashokkumar Barot acquired 49,500 warrants on April 1, 2026 (post-IPO dilution instrument, modest size). No director or key insider has sold shares since listing—a neutral-to-positive signal of no dissent at current prices.
Institutional Footprint
Named institutional holders are not granularly disclosed by the company or available in real-time feeds, but aggregated ownership data and IPO anchor book provide direction:
Key Institutional Holders (Indicative — Anchor Book + Aggregated SEBI Data)
Institutional Commentary:
- Mutual Funds (largest DII segment, 4.88%): ICICI Pru, Aditya Birla Sun Life, and SBI Life are confirmed participants from the IPO anchor book. No material fund flows disclosed recently; holdings likely stable or modestly building.
- FII (3.64%): Small but healthy foreign institutional participation. No signs of panic selling or rapid accumulation. FII tends to wait for better visibility on US market cycles and global pharma pricing dynamics before building larger positions.
- Insurance (aggregate within DII): Typically long-term buy-and-hold; no fund crisis evident.
- Banks/NBFC: Minimal direct equity holdings; more relevant as pledging lenders (see Bajaj Finance pledge, now cleared).
Quality Assessment: Institutional ownership is solid but not crowded. Anchor investors from IPO remain engaged; no major fund has exited. The +0.59% institutional addition in Q4 FY26 suggests the stock is on institutional radar for fundamental reasons (US generics upside, CDMO/CMO optionality), not momentum speculation. However, absolute institutional ownership (13%) is below market average for new-listing pharma, leaving room for passive/active accumulation as the company proves execution post-IPO.
Supply & Demand Calendar (12-Month Outlook)
Supply & Demand Events — 12-Month Outlook
Calendar Commentary:
- Q4 FY26 Results (May 14): The single most important catalyst. Trading window reopens after board approval. Director selling/buying will flag confidence. If results disappoint guidance, FII may reduce positions.
- Index Inclusion: Low probability in next 12 months. Market cap ₹4,367 Cr is below Nifty 100 median (~₹1.5L Cr) and Nifty 500 median (~₹30K Cr); unlikely to qualify. Watch for 2027 rebalance if growth accelerates.
- ESOP Dilution: Immaterial. April 2026 warrant acquisition (49.5K shares) by Viraj Barot is small relative to 45M share base.
- Lock-up Expiry: No surprises. Post-IPO lock-ups (typically 6 months) expired in June 2025. Promoter has not used the expiry to sell.
Net Supply/Demand: Balanced, slightly demand-positive. No major supply event for 12 months. Q4 earnings and margin trajectory are the only catalysts that could move institutional positioning materially.
Short Interest and Borrow
Short interest data for Indian equities is not centrally published (unlike US equity exchanges). NSE does not disclose short selling positions or days-to-cover metrics to the public. Therefore, short interest metrics are unavailable for Senores Pharma.
Inference from available signals:
- Daily Volume: Avg. ~₹11–13 Cr / day (as of Apr–May 2026); adequate for institutional positioning.
- Bid-Ask Spread: Typically 0.1–0.3%; liquid.
- No reported short seller reports or activist shorting campaigns against the company.
Conclusion: Absence of published short interest data does not imply no shorts exist, but no evidence of crowded short interest or systematic naked shorting is visible. Stock is not on NSE's forced-buyback list for failed deliveries.
What to Watch
Ownership Watchpoints
Summary
The Ownership Register is Healthy and Growing.
One-Sentence Watchlist: The first ownership signal to watch is insider trading activity post-Q4 FY26 results approval (May 16+ 2026)—director buying will validate business model confidence, director selling will flag earnings/guidance disappointment risk.
Key Ownership Takeaways:
- Promoter ownership (45.8%) is clean, pledged 0%, and stable at current prices (no selling since IPO). Reaffirms long-term commitment.
- Institutional ownership (13.3%) is modest but growing (+0.59% in Q4). Anchor investors remain; no panic exits.
- Free float (54.2%) is adequate for institutional positioning and daily liquidity. No concentration risk.
- Pledge history cleared in Feb 2026. Temporary Dec 2025–Feb 2026 pledge of 7L shares was tactical liquidity, not structural stress.
- No index inclusion catalysts in next 12 months. Company too small/new; watch 2027 rebalance.
- Next 90 days: Q4 results + FY27 guidance drive ownership sentiment. Results miss = DII/FII flux; results beat = potential 1–2% institutional accumulation.